Targeted Agents in Chronic Lymphocytic Leukemia (CLL): Advancements in Overall Survival Outcomes?

被引：0
|
作者：
Molica, Stefano [1 ]
Shanafelt, Tait D. [2 ]
Allsup, David [3 ]
Giannarelli, Diana [4 ]
机构：
[1] Hull Univ Teaching Hosp NHS Trust, Dept Hematol, Kingston Upon Hull, N Humberside, England
[2] Stanford Univ, Div Hematol, Dept Med, Stanford, CA USA
[3] Castle Hill Hosp, Cottingham, England
[4] B Fdn Policlin Univ A Gemelli, IRCCS, Biostat Unit, Rome, Italy
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180699
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] PROGNOSIS FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    PHILLIPS, E
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1975, 16 (MAR): : 274 - 274
  • [22] Incorporating Targeted Agents Into Future Therapy of Chronic Lymphocytic Leukemia
    Pallasch, Christian P.
    Hallek, Michael
    SEMINARS IN HEMATOLOGY, 2014, 51 (03) : 235 - 248
  • [23] Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI), a Novel Comorbidity Measure, Predicts Outcomes in the Context of Targeted Agents and in a Large National Registry
    Gordon, Max J.
    Kaempf, Andy
    Rotbain, Emelie
    Sitlinger, Andrea
    Shouse, Geoffrey
    Mei, Matthew
    Brander, Danielle M.
    Salous, Tareq
    Hill, Brian T.
    Choi, Michael
    Cohen, Jonathon B.
    Stephens, Deborah M.
    Persky, Dan O.
    Patel, Krish
    Shadman, Mazyar
    Park, Byung
    Niemann, Carsten Utoft
    Danilov, Alexey V.
    BLOOD, 2021, 138
  • [24] Role of Chronic Lymphocytic Leukemia (CLL)-Derived Exosomes in Tumor Progression and Survival
    Nistico, Nancy
    Maisano, Domenico
    Iaccino, Enrico
    Vecchio, Eleonora
    Fiume, Giuseppe
    Rotundo, Salvatore
    Quinto, Ileana
    Mimmi, Selena
    PHARMACEUTICALS, 2020, 13 (09) : 1 - 14
  • [25] The causes of death and the impact of age on the survival of patients with chronic lymphocytic leukemia (CLL).
    Flynn, JM
    Byrd, JC
    Diehl, LF
    BLOOD, 1999, 94 (10) : 298B - 298B
  • [26] Improved overall survival of relapsed chronic lymphocytic leukemia (CLL) patients exhibiting a complex karyotype and treated with idelalisib plus rituximab
    Kreuzer, Karl-Anton
    Furman, Richard
    Stilgenbauer, Stephan
    Dubowy, Ronald
    Kim, Yeonhee
    Munugalavadla, Veerendra
    Lilienweisz, Esther
    Reinhardt, Hans Christian
    Cramer, Paula
    Eichhorst, Barbara
    Hillmen, Peter
    O'Brien, Susan
    Pettitt, Andrew
    Hallek, Michael
    LEUKEMIA & LYMPHOMA, 2017, 58 : 167 - 168
  • [27] Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia
    Visentin, Andrea
    Facco, Monica
    Frezzato, Federica
    Castelli, Monica
    Trimarco, Valentina
    Martini, Veronica
    Gattazzo, Cristina
    Severin, Filippo
    Chiodin, Giorgia
    Martines, Annalisa
    Bonaldi, Laura
    Gianesello, Ilaria
    Pagnin, Elisa
    Boscaro, Elisa
    Piazza, Francesco
    Zambello, Renato
    Semenzato, Gianpietro
    Trentin, Livio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (10): : 612 - 620
  • [28] Prevalence and Economic Burden of Chronic Lymphocytic Leukemia (CLL) in the Era of Oral Targeted Therapies
    Jain, Nitin
    Chen, Qiushi
    Ayer, Turgay
    O'Brien, Susan M.
    Keating, Michael
    Wierda, William
    Kantarjian, Hagop M.
    Jagpreet, Chhatwal
    BLOOD, 2015, 126 (23)
  • [29] Prevalence and economic burden of chronic lymphocytic leukemia (CLL) in the era of oral targeted therapies
    Jain, Nitin
    Chen, Qiushi
    Ayer, Turgay
    Wierda, William
    O'Brien, Susan
    Keating, Michael
    Kantarjian, Hagop
    Chhatwal, Jagpreet
    LEUKEMIA & LYMPHOMA, 2015, 56 : 112 - 113
  • [30] Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) after Idelalisib Therapy Discontinuation
    Barrientos, Jacqueline C.
    Kaur, Manmeen
    Mark, Alexis
    Chung, Jaewon
    Driscoll, Nancy
    Bender, Alison
    Rai, Kanti R.
    BLOOD, 2015, 126 (23)
12345